Background: Examining EndoPAT predictive value of late Major Adverse Cardiovascular Events (MACE) in 270 outpatients (54±12 years, 48% female). EndoScore was determined and patients were followed for MACE (cardiac death, heart attack, revascularization, or cardiac hospitalization) during a mean of 5.8 years. The EndoScore was among many other measurements that were assessed. The authors also compared its value against the conventional FRS (Framingham Risk Score). Results: MACE occurred in 86 patients (31%). 7 years MACE rate was 48% in patients with EndoScore < 0.4 vs. 28% with EndoScore > 0.4 (P = 0.03). Framingham risk score was not higher in patients with MACE. Multivariate analysis identified EndoScore <0.4 as an independent predictor of MACE (P = 0.03). Conclusions: Since 49% of patients whose EndoPAT test indicated poor endothelial function had a MACE during the seven-year study, low EndoScore was shown to be an independent predictor of MACE, and thus may be useful in identifying CV risk. Moreover, it clearly showed that the EndoScore gave important clinical information that goes beyond the traditional Framingham Risk Score assessment. Since CAD is the leading cause of mortality in post-menopausal women, it makes sense that post-menopausal women undergo EndoPAT screening. |
